demonstrated that a STING LNP enhanced NK cell activity in a B16‐F10 melanoma model and showed that the enhanced tumor control was mediated by NK cells rather than CD8+ T cells.[110] Using nanocarriers to deliver STING agonists can improve the half‐life as well as bioavailability, especially if natural CDNs are used. The gene discussed is STING1; the disease is melanoma.